Protagenic Therapeutics, Inc.\New (PTIXW) — SEC Filings
Protagenic Therapeutics, Inc.\New (PTIXW) — 44 SEC filings. Latest: DEF 14A (Dec 5, 2025). Includes 26 8-K, 5 10-Q, 3 DEF 14A.
View Protagenic Therapeutics, Inc.\New on SEC EDGAR
Overview
Protagenic Therapeutics, Inc.\New (PTIXW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a DEF 14A filed on Dec 5, 2025: Protagenic Therapeutics, Inc. (PTIXW) is holding its Annual Meeting of Stockholders on December 31, 2025, virtually, to ratify the appointment of Green Growth CPAs as its independent registered public accounting firm for the fiscal year ending March 31, 2026. This follows the dismissal of MaloneBail
Sentiment Summary
Across 44 filings, the sentiment breakdown is: 8 bearish, 36 neutral. The dominant filing sentiment for Protagenic Therapeutics, Inc.\New is neutral.
Filing Type Overview
Protagenic Therapeutics, Inc.\New (PTIXW) has filed 3 DEF 14A, 5 10-Q, 26 8-K, 2 8-K/A, 2 10-K, 1 DEFA14A, 1 S-1, 2 SC 13G/A, 2 10-K/A with the SEC between Feb 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (44)
Risk Profile
Risk Assessment: Of PTIXW's 39 recent filings, 8 were flagged as high-risk, 15 as medium-risk, and 16 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | N/A |
| Net Income | -$5,927,019 |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $2,722,451 |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- Garo H. Armen
- Colin Stott
- Dr. David M. Epstein
- Mr. David M. S. Johnson
- Garo Armen
Industry Context
Protagenic Therapeutics operates in the biotechnology sector, a highly competitive and capital-intensive industry. Success is heavily dependent on research and development, clinical trial outcomes, and the ability to secure significant funding. The industry faces stringent regulatory hurdles and a long product development cycle, making it prone to high failure rates and significant financial risks.
Top Tags
8-K (7) · filing (7) · delisting (6) · financials (6) · listing-standards (5) · financial-statements (4) · 10-Q (4) · Protagenic Therapeutics (4) · SEC Filing (3) · regulatory-filing (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Annual Meeting Date | December 31, 2025 | Date of the virtual Annual Meeting of Stockholders |
| Record Date | December 9, 2025 | Date for determining stockholders entitled to vote at the Meeting |
| Auditor Dismissal Date | August 7, 2025 | Date MaloneBailey LLP was dismissed and Green Growth CPAs was engaged |
| New Fiscal Year End | March 31, 2026 | New fiscal year end for which Green Growth CPAs will audit financial statements |
| Former Fiscal Year End | December 31, 2024 | Fiscal year for which MaloneBailey LLP issued a 'going concern' opinion |
| Net Loss | $5.93M | Increased from $0.91M year-over-year for the six months ended September 30, 2025, indicating worsening financial performance. |
| Accumulated Deficit | $11.32M | As of September 30, 2025, highlighting significant historical losses and a going concern risk. |
| Working Capital Deficit | $6.85M | As of September 30, 2025, indicating a severe liquidity challenge. |
| Cash in Bank | $2.72M | Increased significantly from $14,531 on March 31, 2025, due to recent financing activities. |
| Capital Raised | $4.3M | From warrant exercises and a capital raise during the six months ended September 30, 2025, providing a temporary cash infusion. |
| Annualized Expense Reduction | $8M | Expected from the restructuring plan, crucial for improving future financial health. |
| Common Shares Outstanding | 1,934,878 | As of November 26, 2025, after a 1-for-14 reverse stock split on May 5, 2025. |
| Write off of receivables | $1,136,038 | A new operating expense for the six months ended September 30, 2025, contributing to the increased loss. |
| SEC File Number | 001-12555 | Identifies the company's filing with the SEC. |
| EIN | 06-1390025 | Employer Identification Number for the company. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Protagenic Therapeutics, Inc.\New (PTIXW)?
Protagenic Therapeutics, Inc.\New has 44 recent SEC filings from Feb 2024 to Dec 2025, including 26 8-K, 5 10-Q, 3 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of PTIXW filings?
Across 44 filings, the sentiment breakdown is: 8 bearish, 36 neutral. The dominant sentiment is neutral.
Where can I find Protagenic Therapeutics, Inc.\New SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Protagenic Therapeutics, Inc.\New (PTIXW) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Protagenic Therapeutics, Inc.\New?
Key financial highlights from Protagenic Therapeutics, Inc.\New's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for PTIXW?
The investment thesis for PTIXW includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Protagenic Therapeutics, Inc.\New?
Key executives identified across Protagenic Therapeutics, Inc.\New's filings include Garo H. Armen, Colin Stott, Dr. David M. Epstein, Mr. David M. S. Johnson, Garo Armen.
What are the main risk factors for Protagenic Therapeutics, Inc.\New stock?
Of PTIXW's 39 assessed filings, 8 were flagged high-risk, 15 medium-risk, and 16 low-risk.
What are recent predictions and forward guidance from Protagenic Therapeutics, Inc.\New?
Forward guidance and predictions for Protagenic Therapeutics, Inc.\New are extracted from SEC filings as they are enriched.